Channel Therapeutics CORP DEF 14A proxy statements
Proxy statements, covering the matters put to shareholders at the annual meeting — board elections, auditor ratification and executive pay.
Pelthos Therapeutics Inc. will hold its 2025 Annual Meeting to elect directors, ratify auditors, and approve a critical waiver for its $18 million convertible note financing, which could lead to significant shareholder dilution.
Channel Therapeutics Corporation is set to merge with LNHC, Inc., a Ligand Pharmaceuticals subsidiary with an FDA-approved product, in a transaction that will rename the combined entity Pelthos Therapeutics Inc. and include a $50.1 million private investment.
Chromocell Therapeutics is seeking stockholder approval for several key proposals, including reincorporation in Nevada, an amendment to its equity incentive plan, and a waiver of the exchange cap for certain financings.